Fishman Jay A Ltd. MI Has $1.87 Million Stock Holdings in Danaher Corporation $DHR

Key Points

• Fishman Jay A Ltd. MI has reduced its holdings in Danaher Corporation by 19.6%, owning 9,460 shares now valued at approximately $1.87 million.
• Danaher reported a better-than-expected quarterly earnings of $1.80 per share, surpassing analyst estimates of $1.64, with revenues reaching $5.94 billion.
• The company has declared a quarterly dividend of $0.32 per share, set to be paid on October 31st, reflecting an annualized yield of 0.6%.

Fishman Jay A Ltd. MI lowered its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 19.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,460 shares of the conglomerate's stock after selling 2,306 shares during the quarter. Fishman Jay A Ltd. MI's holdings in Danaher were worth $1,869,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of DHR. NBC Securities Inc. acquired a new stake in Danaher during the 1st quarter worth $176,000. Vest Financial LLC increased its holdings in shares of Danaher by 73.6% in the first quarter. Vest Financial LLC now owns 5,361 shares of the conglomerate's stock worth $1,099,000 after acquiring an additional 2,273 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Danaher by 34.0% during the first quarter. Sivia Capital Partners LLC now owns 1,890 shares of the conglomerate's stock worth $387,000 after purchasing an additional 480 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Danaher by 7.2% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,067 shares of the conglomerate's stock valued at $219,000 after purchasing an additional 72 shares in the last quarter. Finally, Kennebec Savings Bank grew its position in shares of Danaher by 3.8% in the 1st quarter. Kennebec Savings Bank now owns 3,052 shares of the conglomerate's stock valued at $626,000 after purchasing an additional 111 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on DHR shares. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Evercore ISI lowered their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Finally, Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday, September 2nd. Seventeen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $245.91.

Danaher Stock Performance

Shares of DHR stock opened at $215.05 on Monday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The company has a 50-day simple moving average of $200.19 and a 200 day simple moving average of $197.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market capitalization of $153.98 billion, a price-to-earnings ratio of 45.75, a PEG ratio of 3.06 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher's dividend payout ratio is currently 27.23%.

Insiders Place Their Bets

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 11.20% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.